Revanesse Versa is an innovative dermal filler that treats moderate to severe facial lines, wrinkles, and creases, including the nasolabial folds that run from the corners of your nose to your mouth. Besides reducing the facial lines, it also adds facial volume and plumps your skin. As such, Versa immediately enhances your facial contours, giving you a younger appearance.
Versa Can Treat:
- Skin textural irregularities
- Acne scars
- Wrinkles and creases
- Nasolabial folds
- Loss of facial volume
- Thin or dry lips
- Skin laxity
- Asymmetry issues
Ready to get started with Revanesse? Book an appointment with Treat Yourself Aesthetics Studio, today!
What are the benefits of Revanesse® Versa?
Benefits of Ravenesse Versa Include:
- Non-surgical treatment
- Quick in-and-out treatment
- Immediate results
- Subtle and natural-looking results
- Extremely safe
- Less swelling than other treatments
- Relatively long-lasting results
- No downtime
What are dermal fillers?
Hyaluronic acid is a naturally occurring molecule found in the body that facilitates the skin’s ability to remain hydrated. HA fillers are body-safe gels that can help fill wrinkles, restore volume loss, and refine facial features when injected.
What is Revanesse®?
Revanesse is a name-brand line of hyaluronic acid (HA) based dermal fillers. Revanesse dermal fillers add volume to areas of depletion for a smoother, more youthful appearance. It also adds shape and symmetry to facial features to achieve aesthetic goals. Revanesse is manufactured by a Canadian company calledProllenium Medical Technologies Inc., which has been developing state-of-the-art products in the medical devices industry, focusing on aesthetics, since 2002.
What makes Revanesse® unique?
The Revanesse® formulation is designed for minimal pain, swelling, and downtime. Injections will be a breeze and you’ll rock your results sooner!
Is Revanesse® safe?
The Revanesse® Versa™ formula is well-studied and extremely safe. Over 300 patients with multiple skin types were treated with Revanesse® Versa™+ in three clinical trials, with no severe negative occurrences reported.